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ABSTRACT
Background: The risk to develop colorectal and endometrial cancers among 
subjects testing positive for a pathogenic Lynch syndrome mutation varies, making 
the risk prediction difficult. Genetic risk modifiers alter the risk conferred by inherited 
Lynch syndrome mutations, and their identification can improve genetic counseling. 
We aimed at identifying rare genetic modifiers of the risk of Lynch syndrome 
endometrial cancer.
Methods: A family based approach was used to assess the presence of genetic 
risk modifiers among 35 Lynch syndrome mutation carriers having either a poor 
clinical phenotype (early age of endometrial cancer diagnosis or multiple cancers) 
or a neutral clinical phenotype. Putative genetic risk modifiers were identified by 
Next Generation Sequencing among a panel of 154 genes involved in endometrial 
physiology and carcinogenesis.
Results: A simple pipeline, based on an allele frequency lower than 0.001 and 
on predicted non-conservative amino-acid substitutions returned 54 variants that 
were considered putative risk modifiers. The presence of two or more risk modifying 
variants in women carrying a pathogenic Lynch syndrome mutation was associated 
with a poor clinical phenotype.
Conclusion: A gene-panel is proposed that comprehends genes that can carry 
variants with putative modifying effects on the risk of Lynch syndrome endometrial 
cancer. Validation in further studies is warranted before considering the possible use 
of this tool in genetic counseling.
Oncotarget41109www.impactjournals.com/oncotarget
INTRODUCTION
Lynch Syndrome is caused by mutations in one out 
of four mismatch repair (MMR) genes - MLH1, MSH2, 
MSH6 and PMS2 - and results in a 25% to 75% lifetime 
risk of colorectal cancer and 60% risk of endometrial 
cancer in women [1].
Genetic testing helps estimating the individual 
risk, plan appropriate care, screening and prophylactic 
treatments. Nevertheless, the risk to develop cancer 
conferred by a MMR mutation is modified by both the 
environment and genetic risk modifiers. The identification 
of such genetic risk modifiers can improve risk prediction 
and genetic counseling, through the individualization of 
surveillance programs and the evaluation of benefits versus 
burdens associated with prophylactic strategies [1, 2].
Searching for genetic risk modifiers is a challenge 
due to their expected small effect-size and their non-
pathogenicity in the absence of a pathogenic mutation 
[2–4]. Genome-wide-association studies have identified 
loci and single nucleotide polymorphisms (SNPs) with risk 
modifying effects [5–8]. More recently, Next Generation 
Sequencing (NGS) of the whole genome or combined with 
gene-panels is emerging in genetic diagnostic to detect 
germ-line variants predisposing to cancer [4, 9–11].
Here, NGS combined with a 154 gene-panel was 
used to identify rare variants (minor allele frequency, 
MAF, <0.001) acting as gene-modifiers of Lynch 
syndrome MMR mutations. Unlike cancer somatic 
mutations, which map exclusively on tumor suppressors 
and oncogenes, the carcinogenic effect of germ-line 
variants can be indirect [2, 4, 11], hence they can map 
within but also outside the genes classically associated 
with cancer. A defect in the genome stability conferred 
by a Lynch syndrome MMR mutation can be aggravated 
by disturbed tissue homeostasis. Therefore, as proof of 
principle for Lynch syndrome related endometrial cancer, 
a panel that included genes controlling the endometrial 
physiology and homeostasis (i.e. hormone signaling) 
beside those associated with cancer was complied. 
A family based approach was used: the presence of 
candidate genetic risk modifiers was evaluated among 
35 patients carrying already a MMR mutation and 
characterized by either a poor clinical phenotype (early 
age of diagnosis or the diagnosis of multiple cancers) or 
by a neutral clinical outcome (diagnosis with endometrial 
cancer only and late in life).
RESULTS
Patients
Table 1 shows the clinical features of the women 
enrolled. All were diagnosed with endometrial cancer 
between 31–81 years (mean: 53.1 ± 10.7). Subjects 
belonged to 29 families with a Lynch syndrome mismatch 
repair (MMR) pathogenic mutation, and all women 
carried the mutation. These mutations will be referred 
to as ‘familial MMR mutations’ (Table 1). One familial 
MMR mutation in MSH6 (c.3729_3732dupATTA – 
p.(Phe1245Ilefs*31)) was a founder mutation common to 
nine subjects belonging to six families.
Eleven women were diagnosed with a second Lynch 
syndrome tumor (two in the breast, six in the intestine, 
three in the ovaries). One woman developed colorectal and 
urinary tract cancers and one was diagnosed twice with 
colorectal cancer (14 years apart). Additionally, 14 women 
developed endometrial cancer at the age of 49 or earlier. 
In the following analyses, women diagnosed with more 
than one cancer, or with endometrial cancer before 50 
(49 or younger) are defined as patients with poor clinical 
phenotypes (or outcome, n = 23), whereas 14 patients who 
developed only endometrial cancer and after the age of 50 
are defined as having a neutral clinical phenotype.
Estrogen and cancer related 154 gene-panel
The coding sequences and splice regions (10 non-
coding nucleotides at each exon end) of 154 genes implied 
in endometrial physiology and carcinogenesis were 
explored by Next Generation Sequencing (NGS). Table 2 
overviews the captured panel and Supplemental Table S1 
gives the complete list of genes and the full set of related 
references.
Estrogens are important physiological regulators in 
the endometrium and risk factors for cancer [12]. Hence, 
the capture panel included 47 genes involved in estrogen 
(and progesterone) signaling, comprising genes controlling 
the metabolism and degradation of steroids [12], genes 
directly targeted by the hormone receptors [16–18], genes 
responsive to steroids [17, 19] and genes encoding for 
co-regulators controlling the hormone receptor 
transcriptional activity [16–18]. In addition, 35 oncogenes 
and 63 tumor suppressors were captured [10, 20–22]. NGS 
and Quality Control analyses are described as Supplemental 
Materials (Supplemental Methods, Supplemental Figures S1, 
2 and Supplemental Table S2). Thirty-seven DNA samples 
were sequenced but two were excluded due to low quality 
(12–04-079_22 and 12–04-079_25, Supplemental Materials 
and Table 1). As control of NGS and raw data analyses, two 
samples (12–04-079_6 and 12–04-079_15) were randomly 
selected and subjected to one additional and independent 
library preparation and NGS run and they showed 100% 
concordance between called variants.
Variant analyses
Among the 35 patient’s DNA successfully 
sequenced, 865 independent variants deposited in dbSNP 
database were identified and each subject carried on 
average 245 single nucleotide polymorphisms (SNPs; 
range 207–270). Common SNPs were excluded from 
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further analyses, but since rare dbSNP variants can be 
relevant in our search for genetic risk modifiers [23, 24], 
52 variants with a minor allele frequency (MAF) lower 
than 0.001 were retrieved (Table 2). Of these, 28 were 
missense, one non-sense (stop), 21 were silent and two 
located in non-coding intron/exon boundaries. In addition, 
46 identified variants were not reported in dbSNP, and 
34 of these were never deposited before in any database 
(ExAC, Cosmic, LOVD and HGMD were checked; 
Table 2). Twenty-nine missense, one frame-shift non-
sense, one in frame deletion and one in frame insertion 
of one amino-acid were identified plus 10 silent variants 
and four changes located in the non-coding regions 
flanking an exon (Table 2).
In total, 98 rare variants were identified (dbSNP with 
MAF <0.001 and non-dbSNP deposited). Considering 
only variants affecting the amino-acid sequence, there 
were 57 missense, one amino-acid insertion, one deletion 
(both in-frame) and two non-sense changes. All variants 
were heterozygous (Supplemental Table S3).
Putatively genetic risk modifiers: risk-variants
To predict the functional consequences and potential 
risk modifying effects, variants were curated using defined 
criteria [23–25], literature, controlling manually and in 
combination with bioinformatics tools such as: Alamut 
(version 2.4, Interactive Biosoftware, including SIFT 
and PolyPhen-2), Uniprot, PhosphoSitePlus® (for three-
dimensional structure and post-translational modifications) 
[15], NCBI Clinical Variants, ExAC, NHLBI ESP, LOVD, 
HGMD, Cosmic.
Variants outside the MMR genes were analyzed 
first. The 98 rare variants reported earlier were considered 
plus three SNPs with a MAF ≥ 0.001 previously reported 
as pathogenic or disease related. These were: rs57865060, 
chromosome position Chr15:75012998:delT, with predicted 
protein change CYP1B1:p.(Glu229Lys); rs121918303, 
Chr13:32351535:A > C with predicted protein change 
RXFP2:p.(Thr222Pro); rs56378716, Chr17:56356502: 
A > G, with predicted protein change MPO:p.(Met251Thr).
The resulting 101 variants (Supplemental Table S3) 
were categorized in five groups according to the 
recommendations of the Dutch and British societies for 
clinical genetics [24]: categories 1 and 2 = no effect; 
3 = variants of unknown significance – VUS; 4 = likely 
pathogenic; 5 = pathogenic. Silent and non-coding 
variants were categorized as 1 (none was predicted to 
affect splicing or other regulatory functions). Conservative 
amino acid changes were considered unlikely to affect the 
protein function (category 2), with the exclusion of four 
variants that had been associated with disease or were 
predicted to have damaging effects (Alamut prediction 
tool), which were categorized as 3. The remaining class 
Table 2: Overview of the panel design of 154 estrogen and cancer associated genes with the variants 
identified in 35 subjects analyzed
Variants  identified
Capture plan Total dbSNP deposited* non-dbSNP deposited
No of 
genes nt (Kb) No
Missense + 
non-sense Silent
Intron-
exon
Missense + 
non-sense + 
ins / del Silent
Intron-
exon
ESTROGEN 47 101.407 25 9 4 0 11 0 1
  ligand 
metabolism 10 13.501 3 0 0 0 3 0 0
 target genes 24 46.847 12 6 2 0 3 0 1
 responsive genes 7 10.539 1 0 0 0 1 0 0
 co-regulators 6 30.52 9 3 2 0 4 0 0
ONCOGENES 35 112.56 24 3 5 2 8 6 0
TUMOUR 
SUPPRESS 63 162.306 40 17 9 0 8 4 2
OTHER 9 19.395 9 0 3 0 5 0 1
TOTAL 154 395.668 98 29 21 2 32 10 4
*variants deposited in the dbSNP database with a MAF <0.001.
The list of all variants is given in Supplemental Table S3.
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3 variants were all non-conservative protein changes. 
Eight variants were in category 4, four of which were 
pathogenic (class 5) for disorders other than endometrial 
cancer, hence they were considered as class 4 in the 
present study. Two independent investigators (RA and 
BMJ, of which BMJ is a Clinical Laboratory Geneticist 
with expertise in diagnostics and oncogenetics) performed 
this curation blindly for each other’s results. Supplemental 
Table S3 gives the curation details and the complete 
variant list.
Since genetic risk modifiers have modest effects 
(see discussion), all variants categorized as 3 (provided 
the presence of a non-conservative amino-acid 
substitution) or higher were considered and resulted in 
54 candidate risk-modifiers. Such variants, referred to as 
‘risk-variants’ from now on, were further characterized 
for the following features (Supplemental Table S3): i) 
the presence of cancer somatic (not silent) mutations 
in the same protein region (i.e. max +/−3 amino acids 
from the identified risk-variant; Cosmic database). 
This was considered as an indication that changes in 
the specific protein region could affect function and 
predisposition to cancer; ii) the interspecies protein 
domain conservation; iii) the presence of the same risk-
variant among relatives; iv) the occurrence of the risk-
variant in relevant protein domains; v) the predicted 
consequences based on Alamut, protein in silico 
analysis, literature mining or the occurrence of other 
pathogenic variants/SNPs in the same region; vi) we 
excluded that risk-variants could co-segregate with the 
familial MMR mutation by verifying their localization 
on separate chromosomes (Supplemental Table S3).
The majority of the patients carried one (or more) 
risk-variant in estrogen related genes (19 out of 35 
patients, 54%) and 18 risk-variants were unique (i.e. the 
same variants occurring in relatives were counted only 
once: n = 5). Risk-variants in tumor suppressors were 
observed in 18 patients (49%), and 25 were unique. One 
(or more) oncogene contained nucleotide changes in nine 
patients (26%), and nine were unique.
MMR genes also contained three risk-variants 
beside the familial mutation and these have not been 
computed in the list of 101 variants given so far 
(Figure 1A). Two variants, one in PMS2 -rs116788608, 
Chr7:6035211:T > C, with predicted protein change 
PMS2:p.(Asp286Gly)- and the second in MSH2 - 
rs41295288, Chr2:47702191:A > G with predicted 
p.(Asp596Ser)- were on other chromosomes than the 
familial MMR mutation (MSH6) of these subjects. In 
contrast, MSH6 variant with predicted protein change 
p.(Ala25Ser) (rs267608026, Chr2:48010445:G > T) in 
patient 12–04-079_32 could co-segregate with the MSH6 
familial mutation carried by this subject. Besides these 
three risk-variants, three additional variants in MMR 
genes with MAF < 0.001 were classified in category 2 
(Figure 1A).
Risk-variants are associated with poor clinical 
phenotypes
The distribution of MMR pathogenic mutations did 
not vary between women with poor and neutral clinical 
phenotypes (Table 3), but patients with poor clinical 
phenotypes carried more frequently one or more risk-
variants outside the MMR genes compared with women 
with a neutral phenotype (Table 3 and Figure 1A).
Cox-regression analysis confirmed that increasing 
number of risk-variants was associated with a poor 
clinical phenotype (Supplemental Figure S3). In these 
Kaplan-Meier analyses the curves of subjects with no 
or one risk-variant overlap with each other and are 
separated from the curves of subjects with two, three 
or more than four risk-variants. Table 3 (rows at the 
bottom) also shows a highest statistical significance 
by combining these two groups. Because of this net 
distinction between subjects carrying no or one risk-
variant versus women carrying more than two risk-
variants, in subsequent Kaplan-Meier cox-regression 
analyses we combined patients in these two groups 
(Figure 1B). The presence of two or more risk-variants 
beside the familial MMR mutation was associated with 
the occurrence of poor clinical features. As defined 
earlier, poor clinical features were either a diagnosis of 
endometrial cancer at a young age (<50), or the onset of 
multiple cancers. Subsequently, these two characteristics 
were assessed separately and the presence of two or 
more risk-variants was associated with both (Figure 1B). 
The lifespan among patients with neutral and poor 
clinical phenotypes, extrapolated at 2013 (the date of 
last update of our database), did not vary significantly 
between groups (Table 3, Figure 1B and Supplemental 
Figure S3).
To exclude that multiple risk-variants could 
co-occur because of co-segregation, we verified that all 
risk-variants in one subject were located on separate 
chromosomes. This was confirmed for 16 out of the 
18 subjects. Subject 12–04-079_14 carried risk-variants 
Chr5:112179368:A > G (APC:p.(Asn2693Asp)) and 
Chr5:131915673:G > A (RAD50:p.(Arg224His)) both on 
chromosome 5 (at a distance of about 90 Mb). A second 
patient (12–04-079_13) carried two risk-variants in 
the same gene (NOTCH1). Results did not change by 
considering these four risk-variants as two co-segregating 
haplotypes.
Three possible risk-variants (category 3 or 
higher) were identified in MMR genes (grey shaded 
in Figure 1A), which were not considered in the 
aforementioned analyses because a linkage with 
the MMR familial mutation could not be excluded. 
Nevertheless, when these risk-variants were included, 
results did not change. In fact, two risk-variants that lied 
certainly in other chromosomes than the MMR familial 
mutation – Chr7:6035211:T > C, predicted protein change 
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Figure 1: The number of class 3 (or more) risk-variants correlates with poor clinical phenotypes. A. Heat map showing the 
presence of class 3 (or more) risk-variants in each subject with neutral phenotype (green, N) or with a poor phenotype (orange, poor; Y = young 
age of endometrial cancer diagnosis; M = cancer at multiple sites). The familial MMR mutations (all non-sense but the one carried by subject 
12–04-079_38) are indicated (3rd column). ‘Additional MRR variants’ (4th column) reports the six rare variants (MAF < 0.001) found in MMR 
genes among seven subjects. In particular, MSH6:p.(Arg378Lys) in subject 12–04-079_10 has been already described to be in linkage with 
the familial MSH6:p.(Arg482*) mutation detected in the patient [39]. ‘Total’ (5th column) refers to the total number of risk-variants outside the 
MMR genes identified in each patient. The specific risk-variants are reported at the right as gene name and predicted amino-acid change (for full 
chromosomal coordinates/nucleotide change, see Supplemental Table S3), together with a color code that indicates the gene function. Variants 
previously reported as (likely) pathogenic (categories 4 and 5) are labeled with a starred ‘P’. B. Kaplan-Meier curves showing the occurrence 
of any poor-clinical phenotype feature (Top chart; first events were only considered for statistic), of the diagnosis of endometrial cancer before 
50 (Middle chart), or of the occurrence of a second tumor (Bottom chart; first events were only considered for statistic) in subjects carrying a 
maximum of one risk-variant (indicated as RV) compared to subjects carrying two or more risk-variants outside the MMR gene. The statistical p 
for significance is computed by Log Rank (Mantel-Cox, Test of equality of survival distributions for the different levels of risk-variants; SPSS).
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PMS2:p.(Asp286Gly) and Chr2:47702191:A > G with 
predicted MSH2:p(Asp596Ser)- occurred in patients 
with a poor clinical phenotype, whereas risk-variant 
Chr2:48010445:G > T, with predicted change MSH6:p.
(Ala25Ser), which could be in linkage with the familial 
mutation, occurred in subject 12–04-079_32 having 
a neutral clinical phenotype.
Among 15 subjects there were some 1st and 2nd 
degree parental relationships and they belonged to 
7 families. Among the five families in which members 
had distinct neutral or poor clinical phenotypes, there 
were three families (A, E and F) in which the woman 
with poor phenotype carried two or more risk-variants 
and carried more risk-variants than the relative with a 
neutral phenotype (Supplemental Figure S4). In family 
B, both members carried three risk-variants but the 
woman with neutral phenotype was significantly younger 
than the women with poor phenotype, and the occurrence 
of a poor phenotype later in life cannot be excluded.
Protein characterization in tumors
Immunohistochemistry was used to further 
characterize the protein expression in a limited number 
of endometrial tumor specimens carrying the risk-
variants (formalin-fixed-paraffin-embedded, FFPE). 
Risk-variants and relative predicted protein change were: 
Chr10:43604498:C > A, with predicted protein change 
RET:p.(Asn361Lys); Chr15:75012998:delT, CYP1A1:p.
(Cys457*); Chr15: 99465448:C > T, IGF1R:p.(Thr758Met), 
Chr12:124821523:G > C, NCOR2:p.(Ser1964Cys); Chr22: 
19951274:delAAG, COMT:p.(Lys159del); Chr1:11264 
625:T > G, mTOR:p.(Met1313Leu). We will refer from 
now on to these risk-variants using their predicted protein 
changes. Results on protein expression in the Lynch tumors 
were compared with a panel of sporadic endometrial 
cancers (n = 7) and post-menopausal healthy controls 
(n = 5). The presence of the risk-variant-allele in the Lynch 
tumors was confirmed by Sanger sequence analyses in 
Table 3: distribution of familial MMR mutations and risk-variants outside the MMR genes (class-3 
or more, i.e. putatively risk modifiers) among patients with neutral and poor clinical phenotypes
Neutral tumor phenotype Poor tumor phenotype
No. No. p-value
Total subjects 14** 23**
Lifespan * 64.2 ± 6.0 66.8 ± 14.1 ns#
No. % No. % p-value
MLH1 0 0.0 3 13.6
ns##*
MSH2 2 15.4 6 27.3
MSH6 12 92.3 12 54.5
PMS2 0 0.0 2 9.1
no variant 5 38.5 2 9.1
0.0471##@
one variant 6 46.2 4 18.2
two variants 1 7.7 5 22.7
three variants 1 7.7 8 36.4
four variants 0 0.0 2 9.1
five variants 0 0.0 1 4.5
0 or 1 variant 11 84.6 6 27.3
0.0016###
2 or more var. 2 15.4 16 72.7
*age of subjects in 2013 was used as lifespan (mean age ± standard deviation in years).
**13 and 22 subjects were successfully analyzed by NGS.
***risk-variants, i.e. class-3 or higher, in genes other than the MMR were considered.
#T-test to compare mean values.
##*Chi square, with 3 degrees of freedom.
##@Chi square, with 5 degrees of freedom, Pearson’s: 11.225.
###Fisher exact test, two sided p-value.
ns = non-significant.
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12 samples and none showed loss of heterozygosity (LOH, 
listed in Supplemental Table S4).
Since we found a substantial number or risk-
variants mapping in the estrogen signaling, the expression 
levels of the estrogen receptor (ER-α) and the Ser-167-
phosphorylated form, induced by growth factors (including 
mTOR, IGF1R and RET) and associated with ligand-
independent activation (26–28), were assessed. ER-α and 
phospho-Ser-167-ER-α levels varied between samples, 
with highest expression in non-cancerous endometrium 
(both from healthy controls and normal tissues adjacent to 
cancer cells, i.e. peri-tumoural tissue), intermediate levels 
in well-differentiated cancers and lowest levels in high-
grade lesions (Supplemental Figure S5).
The expression of NCOR2, CYP1A1 and COMT, 
involved in the estrogen signaling (see discussion), and the 
oncogenes mTOR, RET and IGF1R was high in normal 
and cancerous endometrium and varied between samples 
(Figure 2 and Supplemental Figures S5 and S6).
The identified risk-variant p.(Asn361Lys) in the RET 
tyrosine kinase receptor has been previously described in 
Hirschsprung disease. Asn361 is a N-linked glycosylation 
site necessary for correct membrane localization of 
the receptor and mutated RET remains trapped in the 
endoplasmic reticulum (29). Immunohistochemistry on 
sample 12–04-079_7, carrying RET:p.(Asn361Lys), 
clearly shows an aberrant RET cytoplasmic localization 
compared with controls where RET is located at the 
plasma membrane (Figure 2A).
The frame-shift change in CYP1A1 at position 457 
is predicted to replace the cysteine heme-binding site 
(30) with a stop codon thus disrupting the catalytic site 
and causing premature protein termination. Partial and 
localized loss of CYP1A1 expression was observed in the 
tumor carrying this risk-variant (Figure 2B).
Risk-variant p.(Thr758Met) in the tyrosine 
kinase receptor IGF1R is predicted to abolish the 
N-linked glycosylation at residue Asn756 (Figure 2C). 
Glycosylation is needed for correct receptor processing, 
membrane localization and signal transduction (31). 
Specimen 12–04-079_23 carrying this risk-variant 
showed a decreased membrane immuno-localization of the 
IGF1R (Figure 2D), which was confirmed with confocal 
laser scanning microscopy (CLSM; Figure 2E). This 
observation was concomitant with the highest percentage 
of phospho-Ser-167-ER-α staining (Figure 2F), one of 
the downstream target of the IGF1R kinase activity, 
suggestive of a sustained intracellular activation.
DISCUSSION
Genome-wide approaches [5, 6, 32] have 
identified modifiers of the cancer risk conferred by 
pathogenic Lynch syndrome mutations, but additional 
genetic modifiers are predicted to exist. For instance, 
genome-wide studies cannot detect rare variants [33] 
whose risk modifying contribution remains largely 
undetermined. To identify rare genetic modifiers of the 
risk of Lynch syndrome-related endometrial cancer, 
we have screened a panel of 154 genes among a cohort 
of 35 Lynch syndrome related endometrial cancer 
patients. Fifty-four variants with putative risk modifying 
action were selected (risk-variants), which occurred in 
40 genes and the presence of two or more risk-variants 
was associated with poor clinical phenotypes (Figure 1). 
This result is in line with genome-wide studies that have 
shown that risk modifying alleles exert larger risks in 
carriers of multiple variants compared with single-
variant carriers [6].
The rationale used to design the 154 gene-panel and 
the criteria used to select putative risk modifiers derived 
from recent understandings in cancer biology. Cancer 
somatic mutation landscapes have shown that while 
somatic driver mutations inactivate tumor suppressors or 
activate oncogenes, germ-line predisposing variants have 
more subtle effects and do not necessarily give a direct 
growth advantage or cancer phenotype [11]. For these 
reasons, the designed gene-panel included not only cancer 
associated-genes but also genes that are broadly involved 
in the endometrial physiology, like those encoding for 
proteins controlling the estrogen signaling. In line with 
this model suggesting a distinction between germ-line 
predisposing versus somatic driver mutations [11], no 
(germ-line) risk-variant was identified among the genes 
that are most frequently mutated at the somatic level in 
endometrial cancer, such as PTEN, PIK3CA, CTNNB1, 
KRAS (all included in the panel). When endometrial 
cancer somatic mutation landscape (COSMIC database 
[10]) was aligned to the risk modifiers identified in the 
present study, MTOR was the first common gene ranking 
130th among somatic mutations. STK11 and ATM appeared 
as risk modifiers in our screen and are frequently mutated 
somatically [9] but not in endometrial cancer (COSMIC 
database [10]).
Well-established criteria were used to cluster variants 
in categories 1–5 [23–25, 34]. In addition, we considered 
that genetic modifiers are expected to have little or no 
influence in the general population (modest effect-size), 
while influencing the cancer-risk in predisposed subjects, 
i.e. in subjects carrying a penetrant cancer mutation [2]. 
Hence, we considered as putative risk modifiers all 
variants having a likely-pathogenic or pathogenic effect 
(category 4/5) but also those with ‘unclear significance’ 
(category 3), provided that the were missense leading 
to non-conservative amino-acid substitution. In this 
context, the recognition of the role of rare missense 
changes in cancer susceptibility is growing [35]. 
Lower categories (2 and 1, unlikely to have any effect at 
the protein level) were excluded.
Genes such as NOTCH1 (cell-fate determination), 
NCOR2 and NCOA2 (controlling the activity of ER-α), 
COMT (detoxification pathway and estrogen 
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Figure 2: Aberrant expression or localization of RET, CYP1A1 and IGF1R in specimens carrying the respective risk-
variants. A. Immunohistochemical images of tumors bearing the common allele (WT) of RET or the risk-variant RET:p.(Asn631Lys). Note 
the punctuated cytoplasmic pattern in the risk-variant carrying tumor indicative of trapping of the receptor inside the cell. Scale bar = 100 μm. 
B. Immunohistochemical images of endometrial specimens bearing the common allele (WT) of CYP1A1 (control post-menopausal endometrium 
and Lynch syndrome endometrial cancer: left images). Right images, CYP1A1 expression on tumor specimen bearing the p.(Cys457*) risk-
variant, showing one area with loss of expression (arrowhead). Scale bar = 100 μm. C. Canonical consensus and the five glycosylation sequences 
(glycosylation site indicated by red asterisk) in the IGF1R plus the consequent disruption of this consensus caused by risk-variant IGF1R:p.
(Thr768Met). D. Immunohistochemical images of tumor specimens with common allele (WT) of IGF1R or with risk-variant p.(Thr758Met). 
Scale bar = 100 μm. E. Representative confocal laser scanning microscopic (CLSM) images and fluorescence quantification of the membrane/
cytoplasmic fractions of IGF1R in tumor with common allele or with p.(Thr758Met) IGF1R. The box plot represents the distribution of four 
independent samples for common allele and four areas of sample 12–04-079–23 [carrying the p.(Thr758Met) risk-variant]. Asterisk indicates 
a p-value < 0.05, Wilcoxon-Mann-Whitney Rank Sum Test. F. Representative immunohistochemical images (top) and quantification of the 
percentage of nuclei positive to phospho-Ser-167-ER-α among endometrial cancer with wild type IGF1R (the grey bar indicates the mean ± SD 
of seven Lynch syndrome tumor specimens) and with IFG1R:p.(Thr758Met) (black bar, mean ± SD of four independent areas of the tumor from 
subject 12–04-079–23, bearing the variant). Asterisk indicates a p-value < 0.05 compared to common allele (t-test). Scale bar = 100 μm.
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degradation), and classical oncogenes (the tyrosine 
kinase receptors NTRK1 and IGF1R) or tumor 
suppressors (APC, BRCA2, EPHB2 and CDH1, the 
latter being already identified as a risk modifier locus 
in genome-wide studies [6]) carried more than one 
independent risk-variant, indicating that they are hit 
frequently. In addition, the pathways where risk-variants 
were found underscored some signalings in which 
genetic modifier can be found: the STK11/TSC1/mTOR 
cascade; the estrogen signaling at ER-α transcriptional 
control (NCOR2, NCOA2 - both with multiple risk-
variants - and PPARGC1A); or at ligand metabolism 
level, with risk-variants identified in CYP1A1, COMT 
and CYP1B1, phase I and II detoxifying enzymes 
degrading also estrogens via the formation of catechol-
compounds. The CYP1A1 locus was reported previously 
as risk modifier for Lynch syndrome colorectal cancer, 
although data were not confirmed in independent 
studies [5] and common variants in CYP1A1 and in 
other genes controlling the estrogen metabolism have 
been associated with sporadic endometrial cancer [36].
Although it was not possible to assess the 
segregation of the identified risk-variants with the disease 
within the families in our cohort (DNA from unaffected 
relatives with matched life-span was not available), poorer 
phenotypes tended to segregate with a higher number of 
risk-variants among the small number of patient-relatives 
included in our cohort (Supplemental Figure S4).
Further immunohistochemical characterization of a 
limited number of risk-variants showed association with 
protein changes. The estrogen degrading protein CYP1A1 
showed localized loss of expression in the tumor carrying 
CYP1A1:(p.Cys457*). Tyrosine receptors including RET 
and IGF1R have important crosstalk’s with the estrogen 
signaling and are relevant to the endometrial physiology 
[28, 37]. Variant RET:p.(Ans361Lys) impairs RET correct 
membrane localization [29], and was indeed associated 
with aberrant cytoplasmic immunoreactivity in this study. 
Glycosylation of IGF1R is reported to be important for 
cellular localization, response to anti-IGF therapy and 
signaling activation [31]. Variant IGF1R:p.Thr758Met, 
predicted to disrupt one N-linked glycosylation site, was 
associated with diminished membrane IGF1R localization 
and increased phosphorylation of ER-α, one of the 
downstream IGF1R kinase targets. The IGF gene locus 
(coding for the ligand of IGF1R) has been reported as a 
genetic risk modifier for Lynch syndrome [5].
In conclusion, we propose a gene-panel that contains 
potential genetic risk modifiers of Lynch syndrome related 
endometrial cancer in our population. Risk-variants that are 
likely pathogenic have been identified and assessing their 
segregation with the disease phenotypes can be relevant to 
the family members and the subjects assisted at our center.
For implications outside the families of the 
present investigation, the development of gene-panels in 
diagnostics is technically desirable compared to complete 
genome sequencing because it allows achieving sufficient 
coverage, cost effectiveness and simplicity in analyses 
[11, 23]. Therefore, it is intriguing to validate these data 
in independent populations and examine how this panel 
will translate to other ethnicities. The fact that a number of 
risk modifiers identified here correspond to loci that were 
previously characterized in genome-wide investigations is 
encouraging. Additionally, it is possible to improve our 
panel design by including genes recently identified as risk 
modifiers in genome-wide studies [6, 38].
MATERIALS AND METHODS
Ethical statement
Investigation has been conducted in accordance 
with the ethical standards, according to the Declaration 
of Helsinki and according to national and international 
guidelines. Protocols have been approved by the authors’ 
institutional medical ethical committee (see below for 
details).
Patient population
Thirty-seven Dutch Caucasian women from 
29 families who developed hereditary endometrial 
cancer and carried a germ-line mismatch repair (MMR) 
gene mutation were enrolled (Table 1). Women were 
counseled at the Maastricht or Leiden Medical Centers 
(2011–2013) because of a Lynch syndrome family 
history, a Lynch syndrome mutation or a Lynch 
Syndrome diagnosis (Bethesda criteria). Genomic 
DNA was used for Next Generation Sequencing (NGS) 
analyses. All women had given consent to use their 
DNA for research. The local medical ethical committee 
approved the protocol (METC 12–04-079).
Archival formalin-fixed-paraffin-embedded 
(FFPE) tissues of 12 women’s tumor specimen 
were retrieved from the hospitals that performed the 
hysterectomy and they were used for DNA analyses, 
loss of heterozygosity (LOH; n = 12) and histology/
immunohistochemistry (n = 8). Seven sporadic endo-
metrial cancers and five post menopausal healthy 
controls were randomly selected from our tissue-bank 
[12] and used as control for immunohistochemistry 
(local medical ethical committee tissue-bank protocol 
approval: METC-14–04-003).
Gene-panel and NGS
Coding sequences plus intron/exon boundaries of 
2012 regions from 154 genes (396kB; Table 2, Supplemental 
Table S1) and 57 off-target control regions (84kB) were 
designed and captured with Haloplex platform (Agilent 
Technologies, Ratingen, Germany). Illumina HiSeq NGS 
(Illumina, San Diego, USA) was used for sequencing and 
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reads were aligned against the reference genome (GRCh37/
hg19). Variants were called using NextGene (Softgenetics, 
State College, USA), SureCall software packages (Agilent 
Technologies, Ratingen, Germany) plus manual checking, 
which resulted in 0% false positives (confirmed by 
Sanger analyses) and in the successful detection of all 
re- sequenced pathogenic MMR mutations suitable to be 
detected (Supplemental Methods). Sanger sequencing 
was performed using BigDye Termination v.1.1. (Life 
Technologies, Bleiswijk, Netherlands). Detailed descriptions 
of the gene-panel design, capture, library preparation, 
NGS, variant calling and quality controls are given in 
Supplemental Methods. The dbSNP142 - The National 
Center for Biotechnology Information (NCBI) was used to 
identify deposited polymorphisms and variants.
Immunohistochemistry, confocal laser scanning 
microscopy (CLSM) and LOH
Standard protocols [12, 13] and antibody 
manufacturer’s instructions were used for 
immunohistochemistry. Antigens were retrieved with 
tris-EDTA buffer. Antibodies used: estrogen receptor-α 
(ERα; monoclonal D-5, 1:100; Dako, Glostrup, Denmark), 
IGF1R (1:400; monoclonal; Novus Biologicals, Littleton, 
USA), CYP1A1 (1:1000; polyclonal; Sigma-Aldrich, 
St. Louis, USA), COMT (1:100; polyclonal; Sigma-
Aldrich, St. Louis, USA), Phospho-ERα ser167 (1:50; 
monoclonal; Cell Signaling Technology, Danvers, USA), 
RET (1:500; polyclonal; Sigma-Aldrich, St. Louis, USA). 
Chemate Envision and 3,3-diaminobenzidine (Dako, 
Glostrup, Denmark) were used to visualize antibody 
binding. Immunoscores were assessed by two independent 
investigators (DB and RA) as described [12]. Protocols for 
SMRT, Phospho-S6 Ribosomal protein-ser235/236 and 
mTOR staining are given in Supplemental Figure S6.
Confocal laser scanning microscopy (CLSM) was 
performed on 4 μm thick FFPE tissue sections. Anti IGF1R 
(1:250; monoclonal; Novus Biologicals, Littleton, U.S.A.) 
followed by rabbit-α-mouse IgG-FITC (1:100, Dako, 
Glostrup, Denmark) were used. CLSM was performed 
with Leica CTR 4000/CTC SPE and the Application Suite/
advance fluorescence software (Leica Microsystems B.V., 
Rijswijk, Netherlands). Image-J program (v 1.48, National 
Institutes of Health, USA) was used for image analyses.
For LOH, an expert pathologist (VdVKK) identified 
the tumor regions from histological sections of FFPE 
materials, which were resected for genomic DNA isolation 
(QIAamp DNA FFPE tissue kit, Leusden, Netherlands) 
and Sanger sequencing. At least two separate tumor 
regions were analyzed.
Statistical analyses
Kaleidograph (v 4.1, Synergy Software, Reading, 
USA), SPSS (v 22, IBM Corporation, Armonk, USA) and 
the online Simple Interactive Statistical Analysis (SISA) 
were used as indicated in the text.
URLs
Gene browsers
Ensembl Genome Browser: http://www.ensembl.
org; NCBI: http://ncbi.nlm.nih.gov; University of 
California Santa Cruz: UCSC Genome Browser: http://
genome.ucsc.edu.
Variant analyses
dbSNP database Human Build 142: http://ncbi.
nlm.nih.gov; Exome Aggregation Consortium: ExAC, 
v 0.3, (Cambridge, MA, USA; February 2015): http://
exac.broadinstitute.org/; Exome Variant Server, 
NHLBI GO Exome Sequencing Project (ESP, release 
ESP6500SI-V2, March-2015), Seattle, USA: http://
evs.gs.washington.edu/EVS; Leiden Open Variation 
Database: LOVD 3.0: lovd.nl; The Human Gene 
Mutation Database: HGMD (Cardiff University): http://
www.hgmd.cf.ac.uk; Genome of Netherlands project, 
release 5: http://www.nlgenome.nl [14]; Catalogue Of 
Somatic Mutations In Cancer: Cosmic (Sanger Institute): 
http://cancer.sanger.ac.uk; PhosphoSitePlus®: http://
www.phosphosite.org [15].
Gene ontology, expression information
NCBI: http://ncbi.nlm.nih.gov; UniProt 
Knowledgebase: http://www.uniprot.org/uniprot; 
GeneCards (v 3.12.354 March 2015, Weizmann Institute 
of Science): http://www.genecards.org.
Statistics
SISA: http://www.quantitativeskills.com/sisa/.
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